The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag) An important mechanism of action of allogeneic hematopoietic cell transplantation (HCT) is the graft versus leukemia (GVL) effect, and in non-myeloablative conditioning transplantation this immune-mediated effect is the only curative principle. 1 It has been clearly shown that T-cell responses are the main effector mechanisms of the GVL reactions, 2 and in HLAidentical donor-recipient transplantations individual targets recognized by T cells in the graft have been characterized as proteins or protein fragments that are not expressed in the donor, and thus represent neo-antigens to the transferred T cells. mHags may be encoded on the Y chromosome (in sex-mismatched HCT) 3 or be derived from polymorphismsFthat is, singlenucleotide polymorphisms (SNP) that are disparate between donor and recipient. 4 The HER2 protein is a well-characterized tumor-associated antigen (TAA), which is overexpressed in many solid cancers. 5 Limited data are available regarding the expression in hematological malignancies; 6 however, by intracellular staining of 14 acute myeloid leukemia (AML) samples, we could show that two of them expressed HER2 (Figure 1a ). HER2 comprise five non-synonymous SNPs, two of which have a frequency close to 0.5 (positions 1140 and 1170; http://www.genome.utah.edu/genesnps/). By allele-specific RT-PCR for the 1170 SNP of a panel of tumor cell lines, we detected quite frequent homozygous expression, supporting the 1/1 allelic distribution (Figure 1b) . By using the SNEP database, 7 we identified a peptide from the 1170 A (GCC)-P (CCC) polymorphism, which potentially would bind to HLA-A2. By analyzing the actual binding of the peptides through the assembly assay, we showed that the peptides did indeed bind to HLA-A2, although with low affinity (data not shown). We used peptide-loaded dendritic cell (DC) from a homozygous A/A donor to stimulate autologous peripheral blood mononuclear cell (PBMC) for cloning and establishment of a cytotoxic T lymphocyte (CTL) clone specific for the HER2_P peptide as described earlier. 8 This clone (HER2_P#3) was used to show specific cytotoxic activity against the HER2_P peptide loaded to T2 cells, and importantly, absence of recognition of the HER2_A peptide (Figure 2a) . The HLA restriction of the killing was shown by blocking by the HLA class I specific antibody W6/32 ( Figure 2a) . As a next step, we used established tumor cell lines as targets in standard Cr 51 -release assays, showing that both P/P homozygous and heterozygous cell lines were killed by HER2_P#3, whereas A/A homozygous cell lines were not strongly supporting the notion of natural processing and presentation of the HER2_P peptide ( Figure 2 ). It is important to note that cell lines expressing homozygous A/A HER2 (the CAMA-1 cell line; Figure 1 ) could be killed by HER2_P#3 upon loading of exogenous HER2_P peptide (data not shown). To confirm the HLA-A2/peptide specificity of the killing capacity of HER2_P#3, we used a cold target inhibition assay ( Figure 2b ). The lysis of FM55M2 was abrogated by the addition of cold (unlabeled) HER2_P peptide-loaded T2 cells, but not to the same extent as by cold unpulsed T2 cells. FM55M2, CRL-1629 ( Figure 2b ) and FM28 (data not shown) were killed in an HLA-restricted manner, as killing could be blocked by addition of the HLA class I specific mAb W6/32. To support the notion of an in vivo relevance of this HER2-derived mHag, we isolated AML cells from HLA-A2-positive patients for direct cytotoxicity analyses, and showed that HLArestricted lysis of ex vivo AML cells by HER2_P#3 provided expression of the HER2 P allele (AML28), whereas AML cells isolated from A/A homozygous donors were not killed (AML36) (Figure 3) .
The characterization of SNP could be clinically applied, for example, by vaccination to increase the precursor frequency of specific cells in donors before the harvest of cells, or in patients subsequent to HCT. With regard to the in vivo relevance after HCT, it would be interesting to study a suitable donor-patient cohort (HLA-A2 positive, HER2 positive and disparate for SNP 1170) for spontaneous reactivity in the direction of the P-peptide, but also in the A-peptide direction; however, this has so far not been possible because of the lack of appropriate donor-recipient pairs. As our data show that the peptide is expressed in the context of HLA-A2 on the surface of HER2-positive cancer cells, we used EliSpot to study whether we could detect spontaneous T-cell responses in HER2-positive breast cancer patients. However, we were not able to detect such responses (data not shown). Natural immune responses are in most cases very weak, not comparable with responses directed against mHag after HCT; hence, these data are not conclusive with regard to potential relevance in HCT.
Hematopoietic cell transplantation represents a cellular treatment strategy with curative potential in several hematological indications. However, HCT is not unproblematic; first, its clinical efficacy varies immensely among indications, and for some the treatment is not curative. Moreover, the main adverse side effectFgraft versus host (GVH) diseaseFmay be life threatening, and even when manageable, is severely affecting the quality of life in many patients. Thus, characterization of mHags with a suited expression profile may aid the development of strategies that specifically target such mHags after HCT. 
Letters to the Editor
Our data suggest that the reverse immunology strategy used for identification of the HER2_1170 mHag may set the stage for a more selective characterization of mHags with a focus on hematopoietic expression, tumor expression and function of the protein, as well as frequency of the restriction molecule and the SNP.
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This study was supported by grants from The Danielsen Foundation, The Novo Nordisk Foundation, Danish Medical Figure 2 Specificity and functional capacity of the HER2_P#3 T-cell clone as examined by 51 Cr-release assay. Lysis of T2 cells without peptide, pulsed with the HER2_P peptide with or without the addition of the HLA class I-specific antibody W6/32 and lysis of T2 cells pulsed with the HER2_A peptide. For 'T2 þ P' and 'T2 þ P þ W6/32', an additional E:T ratio (12:1) was included (a). Inhibition of specific lysis by cold-target inhibition and antibody blocking. Lysis of the HER2_1170 homozygous (P/P), HLA-A2 þ melanoma cancer-cell line FM55M2 with or without the addition of the HLA class I-specific antibody W6/32, with and without the addition of cold T2 cells unpulsed or pulsed with the HER2_P peptide (inhibitor to target ratio ¼ 20:1). E:T ratio ¼ 12:1. Lysis of the HER2_1170 homozygous (P/P), HLA-A2 þ head and neck cancer-cell line CRL-1629 with or without the addition of the HLA class I-specific antibody W6/32. E:T ratio ¼ 12:1 (b). Measurements are from one experiment and were all made in duplicate (error bars).
Figure 3
Lysis of homozygous P/P ex vivo enriched AML blasts. Lysis of enriched (CD3À; CD19À) AML blasts enriched from two HLA-A2 þ AML patients (AML_28 (P/P) and AML_36 (A/A)). The highly enriched AML blasts were used as target cells with (for AML 28) or without the addition of the HLA class I-specific antibody W6/32 (for AML_28, AML_36). Measurements were made in duplicate, E:T ratio ¼ 9:1. Cytarabine (Ara-C) is the most important element of standard acute myeloid leukemia (AML) treatment regimens since more than 40 years. However, response to Ara-C treatment is marked by significant inter-individual differences and the development of Ara-C resistance is still a major drawback. Differences in DNA sequences, such as single nucleotide polymorphisms (SNPs), may affect the expression and/or function of specific drug protein targets and explain, at least in part, the interindividual variations in the response to specific treatments. Ara-C is a deoxycytidine analog, which blocks DNA synthesis.
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1 Key enzymes within the Ara-C metabolic pathway are the deoxycytidine kinase (DCK), which is important for Ara-C activation and two enzymes that regulate Ara-C degradation: cytidine deaminase (CDA), which catalyses the conversion of Ara-C into inactive Ara-U, and deoxycytidylate deaminases (DCTD), which catalyses the conversion of Ara-CMP into inactive Ara-UMP. 1 The phosphorylation of Ara-C into Ara-CMP by DCK 2 is the rate limiting step for Ara-C activation and is followed by conversion into Ara-CTP, which then competes with dCTP for incorporation into DNA and subsequent block of DNA synthesis (Figure 1 ). 1, 2 In this study, we identified and correlated SNPs of these three critical enzymes within the Ara-C metabolic pathway with drug-induced toxicity and 5-year overall survival (OS) in 360 caucasian AML patients. All the patients were treated within the multicenter trial AML96 of the German Study Initiative Leukemia (DSIL) between 1996 and 2003 (patient characteristics: Table 1 ). Median observation time was 6.2 (4.3-9.0) years. AML FAB-M3 (acute promyelocytic leukemia (APL)) patients were not included and treated in other European trials.
The study was approved by the responsible national ethics committees and was in agreement with the declaration of Helsinki and registered with the NCT number 00180115. Written informed consent was given by all the patients. The treatment schedule was published earlier. 3 Briefly, in individuals aged 60 years or younger, first induction therapy consisted 
